enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Acquires $90,781.20 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 10,020 shares of the business’s stock in a transaction on Friday, December 29th. The shares were purchased at an average cost of $9.06 per share, with a total value of $90,781.20. Following the transaction, the insider now owns 2,017,820 shares in the company, valued at approximately $18,281,449.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

enGene Stock Down 3.0 %

ENGN stock opened at $9.02 on Friday. enGene Holdings Inc. has a twelve month low of $4.42 and a twelve month high of $43.00. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The company has a market cap of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The business’s 50-day simple moving average is $6.71 and its 200 day simple moving average is $9.78.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, research analysts anticipate that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently made changes to their positions in the business. Logos Global Management LP increased its stake in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. Janus Henderson Group PLC acquired a new position in shares of enGene in the 1st quarter worth approximately $17,095,000. SR One Capital Management LP bought a new position in shares of enGene during the 2nd quarter worth approximately $4,715,000. Finally, Altitude Crest Partners Inc. acquired a new stake in enGene in the 1st quarter valued at $2,039,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ENGN shares. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene currently has a consensus rating of “Buy” and an average price target of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.